People are wary of new technology that might infringe on their rights, but there are certain myths about the TSA's use of ...

Approximately 150 subjects will be enrolled, receiving either the therapy or a placebo daily for a 52-week treatment period.

Alto Neuroscience, Inc. ("Alto") (NYSE: ANRO) a clinical-stage biopharmaceutical company focused on the development of novel precision medicines for neuropsychiatric disorders, today announced the ...

Phase 2 study, led by Dr. Antonio Jimeno at the University of Colorado Anschutz Medical Campus will evaluate NT219 in ...

Forty officers and officials of Jammu and Kashmir Police have successfully completed the first phase of a 12-week training course on fingerprint science. As per a statement, the training, held at ...